title: Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2.
abstract: Prostaglandin E2 (PGE2) increases in the circulation of persons with congestive heart failure (CHF), but the cause of this increase is unknown. Prostaglandins are not stored, therefore, they cannot be released in response to congestive heart failure itself but rather need to have their synthesis stimulated by a hormone or some other substance. Prostaglandin E2's biologic properties are nearly identical to four peptide hormones originating from amino acids 1-30 [long acting natriuretic peptide], 31-67 [vessel dilator], 79-98 [kaliuretic peptide] and 99-126 [atrial natriuretic peptide, ANP] of the 126 amino acid ANP prohormone. ANP previously has been found to have no effect on circulating PGE2 concentrations in persons with CHF. The present investigation was designed to determine if one or more of the other three atrial natriuretic peptides might increase PGE2 when infused at their respective 100 ng/kg body weight/minute concentrations for 60 minutes in persons with congestive heart failure. Vessel dilator increased PGE2 8-fold (P<0.001) in the first 20 minutes of its infusion with PGE2 remaining 2-3 fold increased (P<0.05) for 60 minutes after stopping its infusion. Long acting natriuretic peptide did not increase PGE2 until 40 minutes of its infusion but it caused the maximal increase (27-fold; P<0.001) of PGE2 of the three peptide hormones tested. Kaliuretic peptide's stimulated increase of PGE2 also began in a delayed fashion but its effects lasted the longest, with PGE2 being increased (P<0.05) for two hours after the cessation of kaliuretic peptide's infusion. This investigation demonstrates that 1) three endogenous peptide hormones increase PGE2 in the circulation and 2) suggests that the known increase in PGE2 in CHF may be in part secondary to these peptides.
authors.affiliation: Department of Medicine, University of South Florida Health Sciences Center and James A. Haley Veterans Hospital, Tampa 33612, USA. VESELY.DAVID_L@TAMPA.VA.GOV
authors.forename: D L
authors.initials: DL
authors.lastname: Vesely
authors.forename: G I
authors.initials: GI
authors.lastname: Perez-Lamboy
authors.forename: D D
authors.initials: DD
authors.lastname: Schocken
mesh_terms: D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D015232:Dinoprostone / Q000097:blood*; D006333:Heart Failure / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D011498:Protein Precursors; D014665:Vasodilator Agents; C075322:atrial natriuretic factor precursor (79-98); D009320:Atrial Natriuretic Factor; D015232:Dinoprostone